Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression
Roger S. McIntyre(University of Toronto), Andreas Reif(University of Würzburg), István Bitter(Semmelweis University), Albino J. Oliveira‐Maia(Champalimaud Foundation), Philip Gorwood(Inserm), Andrea Fagiolini(University of Siena), Tetsuro Ito(Janssen (United Kingdom)), Allan H. Young(King's College London), Eduard Vieta(Hospital Clínic de Barcelona), Tamara Werner‐Kiechle(Janssen (Germany)), Jozefien Buyze(Instituut voor Tropische Geneeskunde), Yordan Godinov(Goethe University Frankfurt)
Cited by 32
Related Papers
A longitudinal study on the mental health of general population during the COVID-19 epidemic in China
|Brain Behavior and Immunity|2020|2.7k
How mental health care should change as a consequence of the COVID-19 pandemic
|The Lancet Psychiatry|2020|1.9k
Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder
|Bipolar Disorders|2018|1.8k
Common variants conferring risk of schizophrenia
|Nature|2009|1.7k
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy
|Nature Reviews Drug Discovery|2012|1.3k